Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
NOTCH1 mut RB1 wild-type
|
T-cell adult acute lymphocytic leukemia
|
sensitive |
Ribociclib + Everolimus
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture (PMID: 28151717).
|
28151717
|